含Ⅲ型纤连蛋白域蛋白5(FNDC5)检测试剂盒(酶联免疫吸附试验法)
ELISA Kit for Fibronectin Type III Domain Containing Protein 5 (FNDC5)
FRCP2; Irisin; Fibronectin type III repeat-containing protein 2
- 编号SEN576Hu
- 物种Homo sapiens (Human，人) 相同的名称，不同的物种。
- 实验方法双抗夹心
- 反应时长3h
- 检测范围15.6-1,000pg/mL
- 灵敏度最小可检测剂量小于等于5.5pg/mL.
- 样本类型serum, plasma, tissue homogenates and other biological fluids
- 下载 英文说明书 中文说明书
- 规格 48T96T 96T*5 96T*10 96T*100
- 价格 ¥ 3234 ¥ 4620 ¥ 20790 ¥ 39270 ¥ 323400
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
-
产品包装(模拟)
-
产品包装(模拟)
-
实验结果图
-
标准曲线图
-
通过ISO 9001、ISO 13485质量体系认证
特异性
本试剂盒用于检测含Ⅲ型纤连蛋白域蛋白5(FNDC5)，经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制，不可能完成对所有相关或相似物质交叉反应检测，因此本试剂盒有可能与未经检测的其它物质有交叉反应。
回收率
分别于定值血清及血浆样本中加入一定量的含Ⅲ型纤连蛋白域蛋白5(FNDC5)（加标样品），重复测定并计算其均值，回收率为测定值与理论值的比率。
| 样本 | 回收率范围(%) | 平均回收率(%) |
| serum(n=5) | 98-105 | 101 |
| EDTA plasma(n=5) | 81-94 | 84 |
| heparin plasma(n=5) | 87-96 | 91 |
精密度
精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差：取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次，分别计算不同浓度样本的平均值及SD值。
批间差：选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定，每个样本使用同一试剂盒重复测定8次，分别计算不同浓度样本的平均值及SD值。
批内差： CV<10%
批间差： CV<12%
线性
在定值血清及血浆样本内加入适量的含Ⅲ型纤连蛋白域蛋白5(FNDC5)，并倍比稀释成1:2，1:4，1:8，1:16的待测样本，线性范围即为稀释后样本中含Ⅲ型纤连蛋白域蛋白5(FNDC5)含量的测定值与理论值的比率。
| 样本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 85-104% | 79-99% | 84-99% | 83-97% |
| EDTA plasma(n=5) | 89-98% | 80-94% | 92-99% | 86-101% |
| heparin plasma(n=5) | 78-94% | 80-90% | 85-93% | 98-105% |
稳定性
经测定，试剂盒在有效期内按推荐温度保存，其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响，实验室的环境条件需尽量保持一致，尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
实验流程
1. 实验前标准品、试剂及样本的准备；
2. 加样（标准品及样本）100µL，37°C孵育1小时；
3. 吸弃，加检测溶液A100µL，37°C孵育1小时；
4. 洗板3次；
5. 加检测溶液B100µL，37°C孵育30分钟；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分钟；
8. 加终止液50µL，立即450nm读数。
实验原理
将含Ⅲ型纤连蛋白域蛋白5(FNDC5)抗体包被于96孔微孔板中，制成固相载体，向微孔中分别加入标准品或标本，其中的含Ⅲ型纤连蛋白域蛋白5(FNDC5)与连接于固相载体上的抗体结合，然后加入生物素化的含Ⅲ型纤连蛋白域蛋白5(FNDC5)抗体，将未结合的生物素化抗体洗净后，加入HRP标记的亲和素，再次彻底洗涤后加入TMB底物显色。TMB在过氧化物酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的含Ⅲ型纤连蛋白域蛋白5(FNDC5)呈正相关。用酶标仪在450nm波长下测定吸光度(O.D.值)，计算样品浓度。
增值服务
相关产品
| 编号 | 适用物种：Homo sapiens (Human，人) | 应用(仅供研究使用，不用于临床诊断！) |
| RPN576Hu05 | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Hu06 | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Hu07 | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Hu02 | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| EPN576Hu61 | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Hu03 | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Hu01 | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APN576Hu01 | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)活性蛋白 | Cell culture; Activity Assays. |
| APN576Hu61 | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)活性蛋白 | Cell culture; Activity Assays. |
| RPN576Hu04 | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAN576Hu02 | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)多克隆抗体 | WB; IHC; ICC; IP. |
| PAN576Hu04 | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)多克隆抗体 | WB; IHC; ICC; IP. |
| PAN576Hu01 | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)多克隆抗体 | WB; IHC; ICC; IP. |
| LAN576Hu71 | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)多克隆抗体(生物素标记) | WB; IHC; ICC. |
| SEN576Hu | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMN576Hu | 含Ⅲ型纤连蛋白域蛋白5(FNDC5)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
| 杂志 | 参考文献 |
| Diabetes Research and Clinical Practice | Serum irisin levels in new-onset type 2 diabetes [PubMed: 23369227] |
| Journal of diabetes and its complications | Lower circulating irisin is associated with type 2 diabetes mellitus [Pubmed: 23619195] |
| Horm Metab Res. | Inconsistency in circulating irisin levels: what is really happening [Pubmed:24459033] |
| Int J Obes (Lond). | Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in mice [Pubmed:25199621] |
| Molecular and Cellular Endocrinology | Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice [Pubmed:25576856] |
| journal of diabetes | Lower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysis [PubMed: 25494632] |
| The Journal of Maternal-Fetal & Neonatal Medicine | Maternal circulating levels of irisin in intrahepatic cholestasis of pregnancy [PubMed: 26689349] |
| Hormone and Metabolic Research | Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis [Pubmed:27300472] |
| Nature Reviews Endocrinology | Physiology and role of irisin in glucose homeostasis. [pubmed:28211512] |
| Journal of Molecular and Cellular Cardiology | Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice [pubmed:27638193] |
| Biochemical and Biophysical Research Communications | Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma [pubmed:28867187] |
| PLoS One | Differential actions of PPAR-α and PPAR-β/δ on beige adipocyte formation: A study in the subcutaneous white adipose tissue of obese male mice [Pubmed:29351550] |
| International Brazilian Journal of Urology | The Diagnostic Value of FNDC5/Irisin in Renal Cell Cancer. [Pubmed:29522296] |
| Redox Biology | Irisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative … [Doi: 10.1016/j.redox.2018.10.019] |
| Antioxidants & redox signaling | Low serum irisin concentration is associated with poor outcomes in patients with acute pancreatitis and irisin administration protects against experimental acute … [Pubmed: 31250660] |
| Journal of Maternal-Fetal & Neonatal Medicine | Maternal serum, placental, and umbilical venous blood irisin levels in intrahepatic cholestasis of pregnancy [Pubmed: 31590596] |
| Biomed Pharmacother | Identification of irisin as a therapeutic agent that inhibits oxidative stress and fibrosis in a murine model of chronic pancreatitis [Pubmed: 32199226] |
| Irisin Improves Autophagy of Aged Hepatocytes via Increasing Telomerase Activity in Liver Injury [Pubmed: 31976032] | |
| Serum Irisin Predicts Posthepatectomy Complications in Patients with Hepatocellular Carcinoma [Pubmed: 31976024] | |
| DOMESTIC ANIMAL ENDOCRINOLOGY | The myokine Irisin: localization and effects in swine late medium and large antral ovarian follicle [Pubmed: 33120167] |
| Journal of Biomaterials and Tissue Engineering | The Combination of Aerobic and Resistance Exercise Induces Weight Loss via the PGC-1α/Irisin/UCP-1 Pathway [] |
| Evaluation of a recombinant bacillus calmette-guérin vaccine expressing P39-L7/L12 of Brucella melitensis: An immunization strategy against brucellosis in BALB/c … [] | |
| Eur Rev Med Pharmacol Sci | Salivary Irisin: potential inflammatory biomarker in recurrent apthous stomatitis patients [33755963] |
| Metabolites | Pattern of Adiponectin, Osteocalcin, Irisin, FGF-21, and MCP-1 According to the Body Size Phenotype: Could They Be Markers of Metabolic Health in Mexican-Mestizo … [34822430] |
| Eat Weight Disord | Time-restricted feeding prevents metabolic diseases through the regulation of galanin/GALR1 expression in the hypothalamus of mice [34370270] |
| Ir J Med Sci | Eight-week exercise program improved the quality of life of Alzheimer's patients through functional, cognitive, and biochemical parameters [Pubmed:35604540] |
| Biomed Pharmacother | Irisin attenuates sepsis-induced cardiac dysfunction by attenuating inflammation-induced pyroptosis through a mitochondrial ubiquitin ligase-dependent … [Pubmed:35653888] |
| Journal of King Saud University - Science | Interaction of nitric oxide synthase and mitochondrial ATP-sensitive potassium channels in protective impacts of combination therapy with irisin … [] |
